Ebolavirus (EBOV) is the etiology of Ebola hemorrhagic fever (EHF). A major EHF outbreak in 2014–2015 in West Africa claimed >11,000 lives. A licensed vaccine is not available for EHF, although several vaccines have undergone clinical trials. We developed a human adenovirus (Ad) serotype 5-based candidate EHF vaccine based on controlled expression of the EBOV (Makona strain) glycoprotein (GP) as the immunogen. Two clones, AdGP72 and AdGP75, and a control Ad515 vector, were generated and tested for protein expression in vitro and immunogenicity in mice. Eight groups of mice were immunized with three doses of buffer, Ad515, AdGP72, and AdGP75, by two different dose regimens. Three different antigens (AdGP75-infected Vero E6 cell extract and two baculovirus expressed EBOV GP antigens, namely, GP alone or GP with EBOV VP40) were used to evaluate the immune response. Expression studies indicated that full-length GP was cleaved into its component subunits when expressed in mammalian cells through the Ad vectors. Moreover, in coimmunoprecipitation studies, EBOV GP was found to be associated with VP40 when expressed in baculoviruses. The candidate vaccines were immunogenic in mice, as evaluated by enzyme-linked immunosorbent assay using mammalian- or baculovirus-derived antigens. Further characterization and development of the candidate vaccines are warranted.
Get full access to this article
View all access options for this article.
References
1.
AbbinkP, LemckertAA, EwaldBA, et al.Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol, 2007; 81:4654–4663.
2.
AlbarinoCG, ShoemakerT, KhristovaML, et al.Genomic analysis of filoviruses associated with four viral hemorrhagic fever outbreaks in Uganda and the Democratic Republic of the Congo in 2012. Virology, 2013; 442:97–100.
3.
AppaiahgariMB, PandeyRM, and VratiS. Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines. Clin Vaccine Immunol, 2007; 14:1053–1055.
4.
BarretteRW, MetwallySA, RowlandJM, et al.Discovery of swine as a host for the Reston ebolavirus. Science, 2009; 325:204–206.
5.
BiedenkopfN, LierC, and BeckerS. Dynamic phosphorylation of VP30 is essential for Ebola virus life cycle. J Virol, 2016; 90:4914–4925.
6.
BlancheF, CameronB, BarbotA, et al.An improved anion-exchange HPLC method for the detection and purification of adenoviral particles. Gene Ther, 2000; 7:1055–1062.
7.
ChanSY, MaMC, and GoldsmithMA. Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Gen Virol, 2000; 81:2155–2159.
8.
ChenH, XiangZQ, LiY, et al.Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol, 2010; 84:10522–10532.
9.
ClarkeEC, CollarAL, YeC, et al.Production and purification of filovirus glycoproteins in insect and mammalian cell lines. Sci Rep, 2017; 7:15091.
10.
CrosbyCM, and BarryMA. IIIa deleted adenovirus as a single-cycle genome replicating vector. Virology, 2014; 462–463:158–165.
CrosbyCM, NeheteP, SastryKJ, et al.Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines. J Virol, 2015; 89:669–675.
13.
CroyleMA, PatelA, TranKN, et al.Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One, 2008; 3:e3548.
14.
DolnikO, VolchkovaV, GartenW, et al.Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J, 2004; 23:2175–2184.
15.
Escudero-PerezB, VolchkovaVA, DolnikO, et al.Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog, 2014; 10:e1004509.
16.
EwerK, RamplingT, VenkatramanN, et al.A monovalent Chimpanzee adenovirus Ebola vaccine boosted with MVA. N Engl J Med, 2016; 374:1635–1646.
17.
FieldsBN, and HawkinsK. Human infection with the virus of vesicular stomatitis during an epizootic. N Engl J Med, 1967; 277:989–994.
18.
GeisbertTW, and HensleyLE. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med, 2004; 6:1–24.
19.
GireSK, GobaA, AndersenKG, et al.Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science, 2014; 345:1369–1372.
20.
Henao-RestrepoAM, CamachoA, LonginiIM, et al.Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet, 2017; 389:505–518.
21.
Henao-RestrepoAM, LonginiIM, EggerM, et al.Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet, 2015; 386:857–866.
22.
HodgesBL, EvansHK, EverettRS, et al.Adenovirus vectors with the 100K gene deleted and their potential for multiple gene therapy applications. J Virol, 2001; 75:5913–5920.
23.
ItoH, WatanabeS, TakadaA, et al.Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J Virol, 2001; 75:1576–1580.
24.
KortepeterMG, BauschDG, and BrayM. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis, 2011; 204(Suppl 3):S810–S816.
25.
KumarD, GauthamiS, MadalaU, et al.An Ebola vaccine candidate based on controlled expression of antigen through the recombinant adenovirus system. Int J Infect Dis, 2016; 455:420.
26.
Le GuennoB, FormentyP, WyersM, et al.Isolation and partial characterisation of a new strain of Ebola virus. Lancet, 1995; 345:1271–1274.
27.
LeeJE, FuscoML, HessellAJ, et al.Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature, 2008; 454:177–182.
28.
LemckertAA, SumidaSM, HoltermanL, et al.Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol, 2005; 79:9694–9701.
29.
LiJX, HouLH, MengFY, et al.Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health, 2017; 5:e324–e334.
30.
LiuJ, EwaldBA, LynchDM, et al.Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol, 2008; 82:4844–4852.
31.
LiuJ, O'BrienKL, LynchDM, et al.Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature, 2009; 457:87–91.
32.
LuptonHW, LambertRD, BumgardnerDL, et al.Inactivated vaccine for Ebola virus efficacious in guineapig model. Lancet, 1980; 2:1294–1295.
33.
MaizelJVJr., WhiteDO, and ScharffMD.The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology, 1968; 36:115–125.
34.
ManicassamyB, and RongL. Expression of Ebolavirus glycoprotein on the target cells enhances viral entry. Virol J, 2009; 6:75.
35.
MartinesRB, NgDL, GreerPW, et al.Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol, 2015; 235:153–174.
36.
MarziA, EngelmannF, FeldmannF, et al.Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A, 2013; 110:1893–1898.
37.
MastTC, KiersteadL, GuptaSB, et al.International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine, 2010; 28:950–957.
38.
MatthewsDA, CummingsD, EveleghC, et al.Development and use of a 293 cell line expressing lac repressor for the rescue of recombinant adenoviruses expressing high levels of rabies virus glycoprotein. J Gen Virol, 1999; 80(Pt 2):345–353.
39.
MehediM, FalzaranoD, SeebachJ, et al.A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol, 2011; 85:5406–5414.
40.
Mellquist-RiemenschneiderJL, GarrisonAR, GeisbertJB, et al.Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs. Virus Res, 2003; 92:187–193.
41.
MuhlbergerE, LotferingB, KlenkHD, et al.Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes. J Virol, 1998; 72:8756–8764.
42.
NodaT, AoyamaK, SagaraH, et al.Nucleocapsid-like structures of Ebola virus reconstructed using electron tomography. J Vet Med Sci, 2005; 67:325–328.
43.
NodaT, SagaraH, SuzukiE, et al.Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol, 2002; 76:4855–4865.
44.
NwanegboE, VardasE, GaoW, et al.Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol, 2004; 11:351–357.
45.
OkekeMI, NilssenO, MoensU, et al.In vitro host range, multiplication and virion forms of recombinant viruses obtained from co-infection in vitro with a vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus isolate. Virol J, 2009; 6:55.
46.
OkwareSI, OmaswaFG, ZarambaS, et al.An outbreak of Ebola in Uganda. Trop Med Int Health, 2002; 7:1068–1075.
47.
PilankattaR, ChawlaT, KhannaN, et al.The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines. J Med Virol, 2010; 82:407–414.
48.
ReedLJ, and MuenchH. A simple method of estimating fifty percent endpoints. Am J Hyg, 1938; 27:493–497.
49.
ReifJS, WebbPA, MonathTP, et al.Epizootic vesicular stomatitis in Colorado, 1982: infection in occupational risk groups. Am J Trop Med Hyg, 1987; 36:177–182.
50.
RichardsonJS, AbouMC, TranKN, et al.Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs. J Infect Dis, 2011; 204(Suppl 3):S1032–S1042.
51.
RichardsonJS, PilletS, BelloAJ, et al.Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol, 2013; 87:3668–3677.
52.
SanchezA, YangZY, XuL, et al.Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol, 1998; 72:6442–6447.
53.
SantraS, SunY, Korioth-SchmitzB, et al.Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine, 2009; 27:5837–5845.
54.
SullivanNJ, HensleyL, AsieduC, et al.CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med, 2011; 17:1128–1131.
55.
SullivanNJ, MartinJE, GrahamBS, et al.Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol, 2009; 7:393–400.
56.
SullivanNJ, SanchezA, RollinPE, et al.Development of a preventive vaccine for Ebola virus infection in primates. Nature, 2000; 408:605–609.
57.
TapiaMD, SowSO, LykeKE, et al.Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis, 2016; 16:31–42.
58.
UmaM, HegdeSR, RaoPP, et al.A novel point mutation (L70P) inactivates poliovirus 3C protease. Acta Virol, 2018; 62:68–77.
59.
VogelsR, ZuijdgeestD, van RijnsoeverR, et al.Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol, 2003; 77:8263–8271.
60.
VolchkovVE, BeckerS, VolchkovaVA, et al.GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology, 1995; 214:421–430.
61.
VolchkovVE, FeldmannH, VolchkovaVA, et al.Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A, 1998; 95:5762–5767.
62.
VolchkovVE, VolchkovaVA, ChepurnovAA, et al.Characterization of the L gene and 5′ trailer region of Ebola virus. J Gen Virol, 1999; 80(Pt 2):355–362.
63.
VolchkovaVA, FeldmannH, KlenkHD, et al.The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology, 1998; 250:408–414.
64.
WarfieldKL, PostenNA, SwensonDL, et al.Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis, 2007; 15(Suppl 2):S421–S429.
65.
WauquierN, BecquartP, PadillaC, et al.Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis, 2010; 4:e837.
66.
WebbPA, MonathTP, ReifJS, et al.Epizootic vesicular stomatitis in Colorado, 1982: epidemiologic studies along the northern Colorado front range. Am J Trop Med Hyg, 1987; 36:183–188.
67.
[WHO] Report of an International Commission. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ, 1978; 56:271–293.
68.
WHO. Outbreak news. Ebola Reston in pigs and humans, Philippines. Wkly Epidemiol Rec, 2009; 84:49–50.
WilsonJA, BrayM, BakkenR, et al.Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology, 2001; 286:384–390.
71.
WongG, KobingerGP, and QiuX. Characterization of host immune responses in Ebola virus infections. Expert Rev Clin Immunol, 2014; 10:781–790.
72.
XuL, SanchezA, YangZ, et al.Immunization for Ebola virus infection. Nat Med, 1998; 4:37–42.
73.
YangZ, DelgadoR, XuL, et al.Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science, 1998; 279:1034–1037.
74.
YoshidaY, EmiN, and HamadaH. VSV-G-pseudotyped retroviral packaging through adenovirus-mediated inducible gene expression. Biochem Biophys Res Commun, 1997; 232:379–382.
75.
YuJS, LiaoHX, GerdonAE, et al.Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor. J Virol Methods, 2006; 137:219–228.
76.
ZhangAP, BornholdtZA, LiuT, et al.The Ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLoS Pathog, 2012; 8:e1002550.
77.
ZhuFC, HouLH, LiJX, et al.Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet, 2015; 385:2272–2279.
78.
ZhuFC, WurieAH, HouLH, et al.Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 2017; 389:621–628.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
